SC
CATX icon

Sykon Capital’s Perspective Therapeutics CATX Stock Holding History

Sykon Capital’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$158K Hold
37,932
– – 0.05% 86
2025
Q4 		$104K Hold
37,932
– – 0.03% 117
2025
Q3 		$130K Hold
37,932
– – 0.04% 100
2025
Q2 		$130K Hold
37,932
– – 0.05% 83
2025
Q1 		$80.8K Hold
37,932
– – 0.03% 63
2024
Q4 		$121K Hold
37,932
– – 0.04% 62
2024
Q3 		$506K Hold
37,932
– – 0.18% 65
2024
Q2 		$378K Buy
37,932
+34,310
+947% +$496K 0.14% 60
2024
Q1 		$43.1K Buy
+3,622
New +$30.9K 0.02% 92

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sykon Capital's CATX Position: Q1 2026 in Review

Sykon Capital held its Perspective Therapeutics (CATX) position steady in Q1 2026 at 37,932 shares worth $158K. The position accounts for 0.05% of the portfolio, ranked #86.

Sykon Capital first reported a position in CATX in Q1 2024 and has held it in 9 quarters since. The position peaked at $506K in Q3 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Sykon Capital held 37,932 shares of Perspective Therapeutics worth $158K as of Q1 2026.
  • Sykon Capital left its Perspective Therapeutics share count unchanged in Q1 2026.
  • Perspective Therapeutics made up 0.05% of Sykon Capital's portfolio in Q1 2026, its #86 holding.
  • Sykon Capital first reported a position in Perspective Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Sykon Capital's Perspective Therapeutics position peaked at $506K in Q3 2024.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Sykon Capital's 13F filing for Q1 2026, filed 22 Apr 2026.